This morning per a Tandem press release;
“Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced that it intends to use its remote software update tool, the Tandem Device Updater, to resolve a Control-IQ technology software anomaly identified during the ongoing DCLP3 phase of the International Diabetes Closed Loop (IDCL) clinical trial. The Company anticipates that the software update will be available to study sites before the end of March.
“A primary reason for a larger pivotal clinical trial is to identify and resolve infrequent anomalies like this that may not appear . . .
This content is restricted to subscribers. Please subscribe.
Already have an account? Please login.